You just read:

Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose

News provided by

Rockwell Medical

Feb 04, 2013, 07:30 EST